Navigation Links
Duramed's Lo SEASONIQUE(R) NDA Accepted for Filing by FDA
Date:2/25/2008

service our significantly increased debt obligations as a result of the PLIVA acquisition; changes in generally accepted accounting principles; and other risks detailed in our SEC filings, including in our Transition Report on Form 10-K/T for the six months ended December 31, 2006.

The forward-looking statements contained in this press release speak only as of the date the statement was made. The Company undertakes no obligation (nor does it intend) to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except to the extent required under applicable law.


'/>"/>
SOURCE Barr Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Centocor Announces Ustekinumab Biologic License Application Accepted for Filing by FDA
2. New Drug Application for Tolvaptan, Otsukas Investigational Novel Oral Treatment for Worsening Heart Failure and Hyponatremia, Accepted by the U.S. Food and Drug Administration
3. Nitecs IND Application for Clinical Development With Lodotra Accepted by the FDA
4. Neuralstem Shares Accepted for Trading on Amex(R)
5. Attagenes Breakthrough Transcription Factor Profiling Technology to be Described in Nature Methods
6. Addrenex Pharmaceuticals Reaches Milestone with Filing of NDA for First Product, CloniBID, to Treat Hypertension
7. Finkelstein Thompson LLP Announces Filing of Securities Fraud Class Action Against CellCyte Genetics Corporation
8. Oncolytics Biotech Inc. Announces Filing of Phase 1/2 Clinical Trial with REOLYSIN(R)
9. U.S. District Court Decision About Eisais Legal Action Over Aricept ODT(R) ANDA Filing
10. Reliant Pharmaceuticals Announces the Filing of Registration Statement on Form S-1 For an Initial Public Offering
11. FDA Accepts Ranexa(R) sNDA and NDA for Filing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... 2014) – The severe flooding that devastated a wide ... destructive if the bridges, roads and other infrastructure had ... from the University of Colorado Denver. , "People need ... Jimmy Kim, PhD, associate professor of structural engineering at ... and lead author the study. "There is an assumption ...
(Date:10/27/2014)... WORCESTER, Mass. and TORONTO ... Biotechnology Corporation ( www.generex.com ) (OTCQB: GNBT) today ... the immunological response triggered by its novel proprietary ... of relapse in breast cancer patients. The AE37 ... wholly-owned subsidiary, Antigen Express, Inc. ( www.antigenexpress.com ). ...
(Date:10/27/2014)... Florida (PRWEB) October 27, 2014 ... at reducing and eliminating several types of pediatric ... not been achieved in over 30 years of ... Noah's Light Foundation, proves that one mom's determination ... diagnosed just before Halloween trick-or-treating, and it’s only ...
(Date:10/27/2014)... , October 27, 2014 Investor-Edge ... Inc. (NASDAQ: NBIX ), Insmed Inc. (NASDAQ: ... BCRX ), Dyax Corporation (NASDAQ: DYAX ... these five companies can be accessed at: http://investor-edge.com/register ... NASDAQ Composite ended at 4,483.72, up 0.69%, the Dow ...
Breaking Biology Technology:CU Denver study says upgrading infrastructure could reduce flood damage 2Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 2Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 3Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 4FDA Approves Breakthrough in Pediatric Brain Cancer - First in 30 Years 2FDA Approves Breakthrough in Pediatric Brain Cancer - First in 30 Years 3Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 2Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 3Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 4Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 5
... BioMarin,Pharmaceutical Inc. (Nasdaq: BMRN ) today announced ... a company,update at the Credit Suisse 2008 Annual Healthcare ... 10:30 a.m. MST., Interested parties may access a ... section of the BioMarin website, http://www.BMRN.com .,A replay ...
... Stock Exchange Symbol: MS, EDMONTON, Nov. 5 /PRNewswire-FirstCall/ - ... of multiple sclerosis (MS), today,announced that Mr. Kevin Giese, President ... Healthcare Conference in New York., WHEN: ... WHERE: New York Palace Hotel, New York., ...
... that management will present at the following,investor conferences in November., ... New York Palace Hotel Wednesday, November 12, 2008 ... Conference The St. Regis Hotel, New York Tuesday, ... will be audio webcast live and available for replay,from Dendreon,s ...
Cached Biology Technology:BioMarin to Present at the Credit Suisse Healthcare Conference 2BioMS Medical to present at Rodman and Renshaw Annual Healthcare Conference 2
(Date:10/29/2014)... of kidney cancer patients in Europe sheds light on ... an apparent link between exposure to aristolochic acid and ... research, by an international team led by scientists from ... Montreal, underscores the importance of investigating possible sources of ... of the Aristolochia genus, also has been suspected of ...
(Date:10/28/2014)... North America, Europe and China have published a paper ... Sciences that reveals important details about key transitions ... From strange and exotic algae, mosses, ferns, trees and ... and vegetables we eat and the ornamental plants adorning ... a billion years of history., "Our study generated DNA ...
(Date:10/28/2014)... a novel environment are linked to individual differences ... study completed at the University of Eastern Finland ... The study used novel, long-term observations of individual ... analyse if behaviours predict the vulnerability to fishing ... hatchery rearing environments. Based on the results, ...
Breaking Biology News(10 mins):Study sheds light on genetic architecture of kidney cancer 2Study sheds light on genetic architecture of kidney cancer 3New study uses DNA sequences to look back in time at key events in plant evolution 2New study uses DNA sequences to look back in time at key events in plant evolution 3Fish 'personality' linked to vulnerability to angling 2
... have elucidated a key mechanism by which cancer cells ... and raw materials required to sustain runaway growth. ... Ludwig Cancer Research study also reveals how the aggressive ... therapies that should disrupt this capabilityknown as the Warburg ...
... animals will choose to steer clear of dirt but their ... risk of disease as a result. A study of ... near to used nesting material and droppings left by other mice. ... opportunity to eat outweighs an increased risk of disease from other ...
... to learn that individual "molecular muscles" within cells respond to ... cells "feel" the environment and appropriately adapt their shapes and ... 20 in the journal Nature Materials , specifically sheds ... internal signals. A computer model the researchers developed, ...
Cached Biology News:Targeting cancer's sweet tooth 2Targeting cancer's sweet tooth 3Clean living is a luxury wild animals can't afford, study suggests 2Cells' 'molecular muscles' help them sense and respond to their environments 2Cells' 'molecular muscles' help them sense and respond to their environments 3